https://www.pharmaradar360.com/article/inside-cvs-health-s-glp-1-push-and-earnings-beat-cfa9c02070099e13Pharma Surgeen2026-08-06T15:16:55.000ZInside CVS Health's GLP-1 Push and Earnings Beathttps://www.pharmaradar360.com/article/takeda-achieves-major-milestone-with-holistic-narcolepsy-drug-approval-21c7bfbef69fe11ePharma Surgeen2026-08-06T15:16:02.000ZTakeda Achieves Major Milestone With Holistic Narcolepsy Drug Approvalhttps://www.pharmaradar360.com/article/merck-kgaa-lifts-guidance-as-bioprocessing-and-chips-offset-healthcare-2a51f780282e4b2bPharma Surgeen2026-08-06T15:11:40.000ZMerck KGaA lifts guidance as bioprocessing and chips offset healthcarehttps://www.pharmaradar360.com/article/spacemd-s-2028-starfall-mission-could-carry-up-to-32-pil-boxes-ea642c40e99c523fPharma Surgeen2026-08-06T15:00:00.000ZSpaceMD's 2028 Starfall Mission Could Carry Up to 32 PIL-BOXeshttps://www.pharmaradar360.com/article/fda-approves-mflusiva-first-mrna-based-flu-vaccine-170299e2f7f3f2eePharma Surgeen2026-08-06T14:48:56.000ZFDA Approves mFLUSIVA, First mRNA-Based Flu Vaccinehttps://www.pharmaradar360.com/article/pacbio-ceo-steps-down-as-q2-loss-widens-9a20ec3696fef4bcPharma Surgeen2026-08-06T14:45:21.000ZPacBio CEO steps down as Q2 loss widenshttps://www.pharmaradar360.com/article/insmed-catapults-nearly-40-leading-a-biotech-rally-ac427cb539aa90e2Pharma Surgeen2026-08-06T14:40:00.000ZInsmed Catapults Nearly 40%, Leading A Biotech Rallyhttps://www.pharmaradar360.com/article/s-d-born-biotech-advances-potential-type-1-diabetes-therapy-through-global-trial-7c7655fc33553ceePharma Surgeen2026-08-06T14:35:40.000ZS.D.-born biotech advances potential Type 1 diabetes therapy through global trialhttps://www.pharmaradar360.com/article/braveheart-pumps-more-life-into-biotech-ipo-market-with-382m-expected-debut-ecd9431115098dfePharma Surgeen2026-08-06T14:35:08.000ZBraveheart pumps more life into biotech IPO market with $382M expected debuthttps://www.pharmaradar360.com/article/chlamydia-testing-activity-dataset-ctad-specification-and-technical-guidance-6edf4058409b4f2dPharma Surgeen2026-08-06T14:34:35.000ZChlamydia Testing Activity Dataset (CTAD): specification and technical guidancehttps://www.pharmaradar360.com/article/life-sciences-healthcare-goals-12f2a28d6ef19c7dPharma Surgeen2026-08-06T14:31:04.000ZLife Sciences Healthcare Goalshttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-08-06T14:30:03.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-08-06T14:30:03.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/new-manufacturing-method-will-reduce-centralised-production-ae06fba7ea423fd3Pharma Surgeen2026-08-06T14:26:05.000ZNew manufacturing method will reduce centralised productionhttps://www.pharmaradar360.com/article/new-kind-of-flu-shot-is-on-the-way-as-fda-approves-moderna-s-mrna-based-vaccine-9e14b388d0794ea1Pharma Surgeen2026-08-06T14:12:00.000ZNew kind of flu shot is on the way as FDA approves Moderna's mRNA-based vaccinehttps://www.pharmaradar360.com/article/two-fda-approvals-a-new-drug-and-a-new-vaccine-9c378d6bb79068dbPharma Surgeen2026-08-06T13:52:07.000ZTwo FDA approvals — a new drug and a new vaccinehttps://www.pharmaradar360.com/article/iraq-wins-legal-case-in-jordan-for-samarra-pharmaceutical-company-d9dbd8fcb2ea20adPharma Surgeen2026-08-06T13:51:50.000ZIraq wins legal case in Jordan for Samarra Pharmaceutical Companyhttps://www.pharmaradar360.com/article/fda-approves-orzeyful-first-drug-targeting-underlying-cause-of-narcolepsy-dea3e3ca205bb38aPharma Surgeen2026-08-06T13:41:15.000ZFDA Approves Orzeyful, First Drug Targeting Underlying Cause of Narcolepsyhttps://www.pharmaradar360.com/article/biovie-s-stock-sinks-50-as-company-uses-composite-endpoint-to-make-case-for-park-81eb96c81548bc11Pharma Surgeen2026-08-06T13:40:09.000ZBioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s programhttps://www.pharmaradar360.com/article/private-philanthropy-we-need-ethics-to-match-it-ethicist-618535f2ba9e1e63Pharma Surgeen2026-08-06T13:30:31.000ZPrivate Philanthropy: We Need Ethics to Match It — Ethicisthttps://www.pharmaradar360.com/article/why-is-collegium-pharmaceutical-stock-tumbling-today-by-investing-com-2c3797eaa2780d0fPharma Surgeen2026-08-06T13:21:27.000ZWhy is Collegium Pharmaceutical stock tumbling today? By Investing.comhttps://www.pharmaradar360.com/article/fda-approves-moderna-s-mrna-based-flu-vaccine-fd11a47093738791Pharma Surgeen2026-08-06T13:07:44.000ZFDA Approves Moderna's mRNA-Based Flu Vaccinehttps://www.pharmaradar360.com/article/faq-inside-pharma-s-changing-hub-landscape-9e091e3c54b2a0a4Pharma Surgeen2026-08-06T13:06:55.000ZFAQ: Inside Pharma’s Changing Hub Landscapehttps://www.pharmaradar360.com/article/collegium-pharmaceutical-falls-13-on-weak-revenue-guidance-by-investing-com-3474b65a2722e928Pharma Surgeen2026-08-06T13:04:46.000ZCollegium Pharmaceutical falls 13% on weak revenue guidance By Investing.comhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-q2-earnings-call-highlights-cc9fe563d680c202Pharma Surgeen2026-08-06T13:04:01.000ZCollegium Pharmaceutical Q2 Earnings Call Highlightshttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2026-to-2027-46b78a2386536090Pharma Surgeen2026-08-06T13:00:04.000ZWeekly all-cause mortality surveillance: 2026 to 2027https://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-08-06T13:00:04.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-08-06T13:00:04.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-08-06T13:00:04.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/measles-historic-confirmed-cases-notifications-and-deaths-55822ba8c9246f07Pharma Surgeen2026-08-06T13:00:04.000ZMeasles: Historic confirmed cases, notifications and deathshttps://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-08-06T13:00:04.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-08-06T13:00:04.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-08-06T13:00:04.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/belzer-uw-cold-storage-solution-and-belzer-mps-uw-machine-perfusion-solution-man-fa64103e06fba841Pharma Surgeen2026-08-06T12:59:06.000ZBelzer UW® Cold Storage Solution and Belzer MPS® (UW Machine Perfusion Solution): manufactured by Carnamedica (UKRP: Bridge to Life): Updated advice on the contamination of fluid DSI/2026/006 (update to DSI/2023/005)https://www.pharmaradar360.com/article/this-drug-researcher-just-reported-earnings-and-could-keep-rallying-on-biotech-b-4e449dbceb06dc10Pharma Surgeen2026-08-06T12:56:18.000ZThis drug researcher just reported earnings and could keep rallying on biotech bounceback, JPMorgan sayshttps://www.pharmaradar360.com/article/new-kind-of-flu-shot-is-on-the-way-as-the-fda-approves-moderna-s-mrna-based-vacc-845b10e44cc4a0e5Pharma Surgeen2026-08-06T12:49:09.000ZNew kind of flu shot is on the way as the FDA approves Moderna’s mRNA-based vaccinehttps://www.pharmaradar360.com/article/a-scientist-turned-biotech-executive-is-notching-some-wins-and-enjoying-it-905f877db76aeb82Pharma Surgeen2026-08-06T12:29:36.000ZA scientist-turned-biotech executive is notching some wins, and enjoying ithttps://www.pharmaradar360.com/article/user-233d0cc67c665783Pharma Surgeen2026-08-06T12:28:00.000ZUserhttps://www.pharmaradar360.com/article/braveheart-charges-past-expectations-with-382-5m-ipo-to-fund-cardio-drug-from-he-9cb2e293d169d041Pharma Surgeen2026-08-06T12:27:37.000ZBraveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengruihttps://www.pharmaradar360.com/article/beckman-coulter-au-immunochemistry-system-au480-analyzer-63614e258dbfa3b8Pharma Surgeen2026-08-06T12:00:00.000ZBeckman Coulter AU Immunochemistry System - AU480 Analyzerhttps://www.pharmaradar360.com/article/theriva-s-six-patient-cancer-trial-is-designed-to-test-repeat-virus-dosing-b354326e957ccecdPharma Surgeen2026-08-06T12:00:00.000ZTheriva’s Six-Patient Cancer Trial Is Designed to Test Repeat Virus Dosinghttps://www.pharmaradar360.com/article/therivatm-biologics-announces-first-patient-dosed-in-virage2-6aa7aebb535ac51dPharma Surgeen2026-08-06T12:00:00.000ZTheriva™ Biologics Announces First Patient Dosed in VIRAGE2https://www.pharmaradar360.com/article/vivani-medical-announces-successful-dosing-of-all-participants-in-slim-1-a-phase-474ac34b19fd69d2Pharma Surgeen2026-08-06T12:00:00.000ZVivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Managementhttps://www.pharmaradar360.com/article/takeda-s-first-in-class-narcolepsy-drug-claims-fda-approval-7ae7c3d5efaaef02Pharma Surgeen2026-08-06T11:52:10.000ZTakeda's first-in-class narcolepsy drug claims FDA approvalhttps://www.pharmaradar360.com/article/amgen-ecovation-how-amgen-builds-sustainability-into-biotech-52bd0d751ed179dcPharma Surgeen2026-08-06T11:46:30.000ZAmgen Ecovation®: How Amgen Builds Sustainability Into Biotechhttps://www.pharmaradar360.com/article/biovie-reports-positive-phase-2-parkinson-s-results-eyes-pivotal-phase-3-trial-816862cb2259f093Pharma Surgeen2026-08-06T11:44:23.000ZBioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trialhttps://www.pharmaradar360.com/article/240415-03-2029-x-glove-vioglove-plus-7-0-violak-international-a-e-a2b630f8e6a64551Pharma Surgeen2026-08-06T11:27:47.000Z«Ανάκληση της παρτίδας 240415, ημ. λήξης 03/2029 των ιατροτεχνολογικών προϊόντων ‘X-Glove ΓΑΝΤΙΑ ΧΕΙΡΟΥΡΓΙΚΑ ΑΠΟΣΤΕΙΡΩΜΕΝΑ VIOGLOVE PLUS μέγεθος 7.0 ’ της ετ. VIOLAK INTERNATIONAL A.E.»https://www.pharmaradar360.com/article/decision-orphan-registered-medicinal-products-eae3fea943c61349Pharma Surgeen2026-08-06T11:24:15.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/mdd-class-iib-smartbag-liquid-acid-concentrates-91464c840e4983d7Pharma Surgeen2026-08-06T11:18:31.000ZΑνάκληση των παρτίδων του παρακάτω πίνακα του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIb, Smartbag-Liquid Acid Concentrateshttps://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-ultragenyx-pharmaceut-cd394e5b1038f1a7Pharma Surgeen2026-08-06T11:18:12.000ZAnalysts Offer Insights on Healthcare Companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO)https://www.pharmaradar360.com/article/intellia-therapeutics-announces-second-quarter-2026-financial-results-and-busine-c6d2b2cb2b1a9023Pharma Surgeen2026-08-06T11:05:12.000ZIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updateshttps://www.pharmaradar360.com/article/tiziana-life-sciences-announces-purchase-of-shares-by-chief-executive-officer-5de33575906123d0Pharma Surgeen2026-08-06T11:00:00.000ZTiziana Life Sciences Announces Purchase of Shares by Chief Executive Officerhttps://www.pharmaradar360.com/article/medtronic-announces-expanded-ce-mark-indication-for-afferatm-mapping-and-ablatio-e3bf8b480507b3a3Pharma Surgeen2026-08-06T11:00:00.000ZMedtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmiashttps://www.pharmaradar360.com/article/pharvaris-publishes-study-on-aae-c1inh-patient-experience-informing-phase-3-crea-86ada8507fc49633Pharma Surgeen2026-08-06T11:00:00.000ZPharvaris Publishes Study on AAE-C1INH Patient Experience, Informing Phase 3 CREAATE Trial Designhttps://www.pharmaradar360.com/article/kodiak-s-trial-tests-ksi-101-for-macular-edema-secondary-to-inflammation-f5d08ca8dadf9574Pharma Surgeen2026-08-06T11:00:00.000ZKodiak's Trial Tests KSI-101 for Macular Edema Secondary to Inflammationhttps://www.pharmaradar360.com/article/compass-pathways-aug-12-fireside-chat-will-have-live-webcast-c308c39ceef87a19Pharma Surgeen2026-08-06T11:00:00.000ZCompass Pathways' Aug. 12 Fireside Chat Will Have Live Webcasthttps://www.pharmaradar360.com/article/painful-swelling-and-misdiagnoses-disrupted-daily-life-in-pharvaris-study-8c2662128a8f1d8dPharma Surgeen2026-08-06T10:50:00.000ZPainful swelling and misdiagnoses disrupted daily life in Pharvaris studyhttps://www.pharmaradar360.com/article/u-s-fda-accepts-sbla-for-enflonsiatm-clesrovimab-cfor-to-update-its-respiratory-d86f5a4edec71b10Pharma Surgeen2026-08-06T10:45:00.000ZU.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Seasonhttps://www.pharmaradar360.com/article/pharma-companies-reported-fewer-medicine-supply-issues-in-2026-aca6bc47ef735762Pharma Surgeen2026-08-06T10:43:58.000ZPharma companies reported fewer medicine supply issues in 2026https://www.pharmaradar360.com/article/why-the-government-must-urgently-raise-the-nice-cost-effectiveness-threshold-4d7982708db3a142Pharma Surgeen2026-08-06T10:40:20.000ZWhy the government must urgently raise the NICE cost-effectiveness thresholdhttps://www.pharmaradar360.com/article/international-comparisons-in-medicines-spending-and-the-link-to-competitiveness-8dea09510c156d92Pharma Surgeen2026-08-06T10:38:45.000ZInternational comparisons in medicines spending and the link to competitivenesshttps://www.pharmaradar360.com/article/laura-mcmullin-of-daiichi-sankyo-named-as-new-abpi-vice-president-b01d6d3a140cf85fPharma Surgeen2026-08-06T10:36:46.000ZLaura McMullin of Daiichi Sankyo named as new ABPI Vice-Presidenthttps://www.pharmaradar360.com/article/growth-and-skills-levy-a-catalyst-for-the-uk-pharmaceutical-industry-ad22de3459a68185Pharma Surgeen2026-08-06T10:35:18.000ZGrowth and skills levy: A catalyst for the UK pharmaceutical industry?https://www.pharmaradar360.com/article/biotech-s-next-big-bet-a-tenax-study-of-a-heart-failure-treatment-0c4ca1cc10a81760Pharma Surgeen2026-08-06T10:34:12.000ZBiotech’s next big bet: A Tenax study of a heart failure treatmenthttps://www.pharmaradar360.com/article/gen-z-are-turning-to-tiktok-for-career-advice-and-inspiration-finds-new-report-cd11aa969c2d9eefPharma Surgeen2026-08-06T10:31:57.000ZGen Z are turning to TikTok for career advice and inspiration, finds new reporthttps://www.pharmaradar360.com/article/greg-you-ve-got-to-bring-back-this-platform-how-lifemine-won-over-gates-and-bezo-58776f7e07d2fbcePharma Surgeen2026-08-06T10:30:00.000Z‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series Ehttps://www.pharmaradar360.com/article/eli-lilly-raises-2026-outlook-again-as-q2-soars-past-estimates-b594bd48b529497bPharma Surgeen2026-08-06T10:28:08.000ZEli Lilly raises 2026 outlook again as Q2 soars past estimateshttps://www.pharmaradar360.com/article/reinventing-reputation-one-of-pharma-s-biggest-challenges-54cfe8757f47d101Pharma Surgeen2026-08-06T10:25:13.000ZReinventing Reputation: one of pharma's biggest challengeshttps://www.pharmaradar360.com/article/abpi-respond-to-wes-streeting-s-commitment-to-boosting-the-economy-through-the-l-4aa596ae5888fd63Pharma Surgeen2026-08-06T10:23:54.000ZABPI respond to Wes Streeting’s commitment to boosting the economy through the life sciences sectorhttps://www.pharmaradar360.com/article/rethinking-sterile-product-development-for-manufacturing-success-de03186e2c6fc007Pharma Surgeen2026-08-06T10:23:07.000ZRethinking sterile product development for manufacturing successhttps://www.pharmaradar360.com/article/abpi-welcomes-labour-s-life-sciences-plan-5d04023111eae18fPharma Surgeen2026-08-06T10:21:38.000ZABPI welcomes Labour's life sciences planhttps://www.pharmaradar360.com/article/3139ffeba101896bPharma Surgeen2026-08-06T10:20:44.000ZΣύσκεψη στον ΕΟΦ για την ομαλή λειτουργία της εφοδιαστικής αλυσίδας των φαρμάκων.https://www.pharmaradar360.com/article/understanding-nhs-medicines-spending-in-england-cd4848213e0a07ddPharma Surgeen2026-08-06T10:16:42.000ZUnderstanding NHS medicines spending in Englandhttps://www.pharmaradar360.com/article/gillibrand-scott-seek-fda-plan-on-chemotherapy-drug-shortages-b7621186f1a5cd55Pharma Surgeen2026-08-06T10:03:37.000ZGillibrand, Scott seek FDA plan on chemotherapy drug shortageshttps://www.pharmaradar360.com/article/mergers-as-strategic-architecture-rethinking-how-to-evaluate-the-astrazeneca-bms-5e14674f98cdcbb8Pharma Surgeen2026-08-06T10:02:44.000ZMergers as Strategic Architecture: Rethinking How to Evaluate the AstraZeneca–BMS Rumorshttps://www.pharmaradar360.com/article/context-scraps-bispecific-t-cell-engager-program-to-extend-cash-runway-deeper-in-3cee9dbd62b9c864Pharma Surgeen2026-08-06T09:55:15.000ZContext scraps bispecific T-cell engager program to extend cash runway deeper into 2027https://www.pharmaradar360.com/article/centre-imposes-tougher-penalties-for-fake-drug-approval-data-82a515088785a1d1Pharma Surgeen2026-08-06T09:51:11.000ZCentre imposes tougher penalties for fake drug approval datahttps://www.pharmaradar360.com/article/glenmede-trust-co-na-acquires-44-273-shares-of-teva-pharmaceutical-industries-lt-c277454fca69ebcbPharma Surgeen2026-08-06T09:39:48.000ZGlenmede Trust Co. NA Acquires 44,273 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/onconic-s-gerd-drug-jaqbo-wins-first-overseas-approval-in-india-57405c4ad7e906ffPharma Surgeen2026-08-06T09:34:40.000ZOnconic’s GERD drug Jaqbo wins first overseas approval in Indiahttps://www.pharmaradar360.com/article/a1adfbf3ea7345cfPharma Surgeen2026-08-06T09:32:32.000ZΦαρμακευτικά προϊόντα που περιέχουν δεσογεστρέλη και ετονογεστρέλη: Απευθείας επικοινωνία προς επαγγελματίες υγείαςhttps://www.pharmaradar360.com/article/why-global-pharmaceutical-reforms-are-quietly-redirecting-rare-disease-innovatio-b876733305dfdef2Pharma Surgeen2026-08-06T09:30:00.000ZWhy global pharmaceutical reforms are quietly redirecting rare disease innovationhttps://www.pharmaradar360.com/article/al-biotech-facility-focused-on-rare-diseases-to-close-lay-off-47-8dbdfcf35d1e41e5Pharma Surgeen2026-08-06T09:10:00.000ZAL biotech facility focused on rare diseases to close, lay off 47https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-08-06T09:03:18.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/registration-procedure-for-veterinary-medicinal-products-with-a-centralised-mark-9b89e709f65a2fa4Pharma Surgeen2026-08-06T08:56:56.000ZREGISTRATION PROCEDURE FOR VETERINARY MEDICINAL PRODUCTS WITH A CENTRALISED MARKETING AUTHORISATIONhttps://www.pharmaradar360.com/article/ec6667ff9bc032f9Pharma Surgeen2026-08-06T08:55:10.000ZΔΙΑΔΙΚΑΣΙΑ ΚΑΤΑΧΩΡΙΣΗΣ ΚΤΗΝΙΑΤΡΙΚΩΝ ΦΑΡΜΑΚΩΝ ΜΕ ΚΕΝΤΡΙΚΗ ΑΔΕΙΑ ΚΥΚΛΟΦΟΡΙΑΣhttps://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-bvs-tvtx-odtx-crl-climb-with-q2-results-acrs-fd9113c8cc53d56ePharma Surgeen2026-08-06T08:54:00.000ZBiotech Stocks At 52-Week Highs - BVS, TVTX, ODTX, CRL Climb With Q2 Results, ACRShttps://www.pharmaradar360.com/article/registration-and-variation-procedure-for-veterinary-medicinal-products-with-a-ce-b476233a56c133bePharma Surgeen2026-08-06T08:51:48.000ZREGISTRATION AND VARIATION PROCEDURE FOR VETERINARY MEDICINAL PRODUCTS WITH A CENTRALISED MARKETING AUTHORISATION (MA)https://www.pharmaradar360.com/article/c523a00ad59cea38Pharma Surgeen2026-08-06T08:30:48.000ZΔΙΑΔΙΚΑΣΙΑ ΚΑΤΑΧΩΡΙΣΗΣ ΚΑΙ ΤΡΟΠΟΠΟΙΗΣΗΣ ΚΤΗΝΙΑΤΡΙΚΩΝ ΦΑΡΜΑΚΩΝ ΜΕ ΚΕΝΤΡΙΚΗ ΑΔΕΙΑ ΚΥΚΛΟΦΟΡΙΑΣ (Α.Κ.)https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-08-06T08:30:05.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884Pharma Surgeen2026-08-06T08:30:04.000ZMpox clade Ib and clade IIb outbreak: epidemiological overviewhttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-b306771583db51dfPharma Surgeen2026-08-06T08:30:02.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in Englandhttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-e72ee03f6bc9d959Pharma Surgeen2026-08-06T08:30:02.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in Englandhttps://www.pharmaradar360.com/article/cosmogen-asquan-equip-biotech-beauty-brand-with-refill-sun-care-stick-f95ace39d14093cbPharma Surgeen2026-08-06T08:25:42.000ZCosmogen & Asquan equip biotech beauty brand with refill sun care stickhttps://www.pharmaradar360.com/article/how-burning-rock-biotech-limited-bnr-affects-rotational-strategy-timing-b4609d12813b2615Pharma Surgeen2026-08-06T08:20:01.000ZHow Burning Rock Biotech Limited (BNR) Affects Rotational Strategy Timinghttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-innovation1-biotech-inc-otc-ivbt-0a476b55799dcb4fPharma Surgeen2026-08-06T08:14:41.000ZEnterprise value to EBIT forward of Innovation1 Biotech Inc. – OTC:IVBThttps://www.pharmaradar360.com/article/portable-gas-detection-in-the-pharmaceutical-sector-016ce0e5916d168dPharma Surgeen2026-08-06T07:59:32.000ZPortable gas detection in the pharmaceutical sectorhttps://www.pharmaradar360.com/article/cumberland-pharmaceuticals-cpix-stock-cools-as-cash-rich-biotech-pivot-begins-d504ed124069cca3Pharma Surgeen2026-08-06T07:40:40.000ZCumberland Pharmaceuticals (CPIX) Stock Cools As Cash Rich Biotech Pivot Beginshttps://www.pharmaradar360.com/article/table-fuji-pharmaceutical-9-mth-group-results-3f4f507a7929b2ccPharma Surgeen2026-08-06T07:30:20.000ZTABLE-Fuji Pharmaceutical - 9-MTH group resultshttps://www.pharmaradar360.com/article/this-simple-tool-may-bring-caries-to-a-halt-50c0601a5220edd3Pharma Surgeen2026-08-06T07:30:00.000ZThis simple tool may bring caries to a halthttps://www.pharmaradar360.com/article/promising-treatments-for-aggressive-cancer-emerge-from-phase-3-trial-c6d0f4fb6392519ePharma Surgeen2026-08-06T07:21:20.000ZPromising treatments for aggressive cancer emerge from phase 3 trialhttps://www.pharmaradar360.com/article/k-pharma-expands-push-into-latin-america-c6659e7c10c2b2aaPharma Surgeen2026-08-06T07:20:16.000ZK-Pharma Expands Push Into Latin Americahttps://www.pharmaradar360.com/article/guidance-clinical-investigations-compiling-a-submission-c9d6540f2d54d8cdPharma Surgeen2026-08-06T07:16:12.000ZGuidance: Clinical investigations: compiling a submissionhttps://www.pharmaradar360.com/article/ultragenyx-rare-stock-revenue-record-clashes-with-ongoing-cash-burn-bf90e5c9f9c8e78aPharma Surgeen2026-08-06T07:06:23.000ZUltragenyx (RARE) Stock Revenue Record Clashes With Ongoing Cash Burnhttps://www.pharmaradar360.com/article/model-van-diergeneeskundig-voorschrift-nieuwe-verplichte-vermeldingen-6f913646dc142d52Pharma Surgeen2026-08-06T07:05:54.000ZModel van diergeneeskundig voorschrift: nieuwe verplichte vermeldingenhttps://www.pharmaradar360.com/article/cros-vs-biotechs-finding-the-right-fit-20569bf843b94165Pharma Surgeen2026-08-06T07:02:54.000ZCROs vs. biotechs: Finding the right fithttps://www.pharmaradar360.com/article/could-helus-pharma-s-new-ceo-reframe-cybin-s-help-path-from-clinical-trials-to-c-9cd80a1d808149f6Pharma Surgeen2026-08-06T06:49:30.000ZCould Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale?https://www.pharmaradar360.com/article/maharashtra-fda-to-fast-track-restoration-of-suspended-food-business-licences-tu-c1236f1370ce02daPharma Surgeen2026-08-06T06:12:00.000ZMaharashtra FDA to fast-track restoration of suspended food business licences: Tukaram Mundhehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hunan-dajiaweikang-pharmaceutical-industry-c-9141db8e148bd7c6Pharma Surgeen2026-08-06T05:03:57.000ZEnterprise value to EBIT forward of Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. Class A – SZSE:301126https://www.pharmaradar360.com/article/exelixis-announces-second-quarter-2026-financial-results-and-provides-corporate-8a9b3c9e3db99e5bPharma Surgeen2026-08-06T04:36:19.000ZExelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Updatehttps://www.pharmaradar360.com/article/south-korean-firm-develops-human-fat-skin-booster-to-treat-ozempic-face-594fe32a637258b2Pharma Surgeen2026-08-06T04:25:26.000ZSouth Korean firm develops human fat skin booster to treat ‘Ozempic face’https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-zhuzhou-qianjin-pharmaceutical-co-ltd-clas-8866f4d81f23ae19Pharma Surgeen2026-08-06T04:22:24.000ZEnterprise value to EBITDA forward of Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A – SSE:600479https://www.pharmaradar360.com/article/how-emerging-biotech-companies-should-choose-a-cro-partner-061bfc4be3818771Pharma Surgeen2026-08-06T03:19:10.000ZHow Emerging Biotech Companies Should Choose a CRO Partnerhttps://www.pharmaradar360.com/article/child-died-in-chinese-biotech-firm-s-gene-editing-trial-e83ecb7856e6e4b0Pharma Surgeen2026-08-06T03:05:12.000ZChild Died in Chinese Biotech Firm’s Gene Editing Trialhttps://www.pharmaradar360.com/article/dimerix-limited-sbmjf-presents-at-2026-bioshares-biotech-summit-new-zealand-slid-922e3726579bab1fPharma Surgeen2026-08-06T03:04:21.000ZDimerix Limited (SBMJF) Presents at 2026 Bioshares Biotech Summit - New Zealand - Slideshowhttps://www.pharmaradar360.com/article/price-to-book-forward-of-goldenwell-biotech-inc-otc-gwll-087b0e37cc8b401dPharma Surgeen2026-08-06T02:59:27.000ZPrice to book forward of GOLDENWELL BIOTECH INC. – OTC:GWLLhttps://www.pharmaradar360.com/article/synthekine-appoints-veteran-biotech-leader-susan-m-molineaux-ph-d-as-chief-execu-a69e56e7529a33bcPharma Surgeen2026-08-06T02:42:34.000ZSynthekine Appoints Veteran Biotech Leader Susan M. Molineaux, Ph.D. as Chief Executive Officerhttps://www.pharmaradar360.com/article/blackrock-inc-buys-ultragenyx-pharmaceutical-inc-rare-sha-544560eae2eeca47Pharma Surgeen2026-08-06T02:37:30.000ZBlackRock, Inc. Buys Ultragenyx Pharmaceutical Inc (RARE) -- Shahttps://www.pharmaradar360.com/article/deepnoid-s-remote-reading-platform-axonflow-wins-south-korean-fda-approval-expan-8a790d5a0145c8ffPharma Surgeen2026-08-06T02:06:00.000ZDeepnoid's Remote Reading Platform 'AxonFlow' Wins South Korean FDA Approval, Expanding Medical AI Serviceshttps://www.pharmaradar360.com/article/prioritisation-activity-in-the-june-quarter-6cdb0633209e2f46Pharma Surgeen2026-08-06T02:00:00.000ZPrioritisation activity in the June quarterhttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-next-generation-enzymatic-dna-synthesis-advanced-nucleases-e7773c88b4c1b53ePharma Surgeen2026-08-06T01:30:29.000ZThe biotech bi-weekly: next-generation enzymatic DNA synthesis, advanced nucleases and AI-driven biologics drug discoveryhttps://www.pharmaradar360.com/article/onconic-wins-india-approval-for-ja-q-bo-accelerates-global-commercialization-cho-1176ddee992a5516Pharma Surgeen2026-08-06T01:25:00.000ZOnconic wins India approval for Ja Q Bo, accelerates global commercialization - CHOSUNBIZhttps://www.pharmaradar360.com/article/innovent-announces-first-patient-dosed-in-pivotal-registrational-study-of-ibi363-4f9199d857eb6df2Pharma Surgeen2026-08-06T00:33:27.000ZInnovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in Chinahttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-68726f95fc90c031Pharma Surgeen2026-08-06T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-032db2a0c1ddaf39Pharma Surgeen2026-08-06T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-30a50cbd2e9a1c2ePharma Surgeen2026-08-06T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-c05a8617653ff9e7Pharma Surgeen2026-08-06T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-36bd3996ef569320Pharma Surgeen2026-08-06T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-a3ce923b37aea348Pharma Surgeen2026-08-06T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-6c8f654e08f19173Pharma Surgeen2026-08-06T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-58c893ab540633e5Pharma Surgeen2026-08-06T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-4f7b900550cd74c8Pharma Surgeen2026-08-06T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-91ceaee1052c3634Pharma Surgeen2026-08-06T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-92e4f339e8e57e86Pharma Surgeen2026-08-06T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-5c2bd1ffe95c7d66Pharma Surgeen2026-08-06T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-7d0d3ea8c622f9d2Pharma Surgeen2026-08-06T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-a584b34e56fb5d44Pharma Surgeen2026-08-06T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-c3e1aaf154b9e213Pharma Surgeen2026-08-06T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/announcement-of-the-intent-to-award-a-single-source-cooperative-agreement-to-bur-c6443986225e29cdPharma Surgeen2026-08-06T00:00:00.000ZAnnouncement of the Intent To Award a Single-Source Cooperative Agreement to Burke Law Group, PLLC in Houston, Texashttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-the-impact-of-clinical-research-train-6fb120477ba67282Pharma Surgeen2026-08-06T00:00:00.000ZProposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)https://www.pharmaradar360.com/article/national-institute-of-dental-craniofacial-research-notice-of-meeting-e2a5143f0126caaePharma Surgeen2026-08-06T00:00:00.000ZNational Institute of Dental & Craniofacial Research; Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-7db89e409dc9fe44Pharma Surgeen2026-08-06T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Organ Procurement and Transplantation Network Board of Directors and Committee Member Applications and Formshttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-4544fe39ca384c52Pharma Surgeen2026-08-06T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-d288b3740496edaePharma Surgeen2026-08-06T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/authorization-of-emergency-use-of-an-in-vitro-diagnostic-device-in-response-to-a-14374fc0e5d2e1cbPharma Surgeen2026-08-06T00:00:00.000ZAuthorization of Emergency Use of an In Vitro Diagnostic Device in Response to an Outbreak of Mpox; Availabilityhttps://www.pharmaradar360.com/article/medical-devices-radiology-devices-classification-of-the-fludeoxyglucose-f18-guid-6a022fe6744749dePharma Surgeen2026-08-06T00:00:00.000ZMedical Devices; Radiology Devices; Classification of the Fludeoxyglucose F18-Guided Radiation Therapy Systemhttps://www.pharmaradar360.com/article/evaluating-the-safety-of-antimicrobial-new-animal-drugs-with-regard-to-their-mic-5aef8613a7479873Pharma Surgeen2026-08-06T00:00:00.000ZEvaluating the Safety of Antimicrobial New Animal Drugs With Regard to their Microbiological Effects on Bacteria of Human Health Concern; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meeting-a534c68a2696aff0Pharma Surgeen2026-08-06T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/gh-research-reports-second-quarter-2026-financial-results-and-provides-business-3c8e5ce202504c0dPharma Surgeen2026-08-06T00:00:00.000ZGH Research Reports Second Quarter 2026 Financial Results and Provides Business Updatehttps://www.pharmaradar360.com/article/bausch-health-ceo-thomas-j-appio-joins-bausch-lomb-board-1a47d2cef43cd74cPharma Surgeen2026-08-06T00:00:00.000ZBausch Health CEO Thomas J. Appio Joins Bausch + Lomb Boardhttps://www.pharmaradar360.com/article/data-monitoring-committees-in-chinese-clinical-trials-institutional-empowerment-2bc887cbc412b0c4Pharma Surgeen2026-08-06T00:00:00.000ZData Monitoring Committees in Chinese Clinical Trials: Institutional Empowerment and the New Landscape of Global Pharmaceutical Innovationhttps://www.pharmaradar360.com/article/the-role-of-a-specialized-hospital-in-the-treatment-of-testicular-germ-cell-tumo-5fff4e142a94cc14Pharma Surgeen2026-08-06T00:00:00.000ZThe role of a specialized hospital in the treatment of testicular germ cell tumors (literature review, case studies)https://www.pharmaradar360.com/article/use-of-balloon-tamponade-device-for-aortoesophageal-fistula-a-case-report-aab463a83a494880Pharma Surgeen2026-08-06T00:00:00.000ZUse of Balloon Tamponade Device for Aortoesophageal Fistula: A Case Reporthttps://www.pharmaradar360.com/article/berberine-poisoning-with-polymorphic-ventricular-tachycardia-a-case-report-417013ff65709cbcPharma Surgeen2026-08-06T00:00:00.000ZBerberine Poisoning with Polymorphic Ventricular Tachycardia: A Case Reporthttps://www.pharmaradar360.com/article/influence-of-clinical-and-demographic-factors-on-the-two-year-results-of-arthrom-bb7dbe7f6ea321c0Pharma Surgeen2026-08-06T00:00:00.000ZInfluence of clinical and demographic factors on the two-year results of arthromedullar bypass in gonarthrosishttps://www.pharmaradar360.com/article/incidence-profile-of-side-effects-of-anti-tuberculosis-drugs-and-adherence-to-ta-f260228d7c4bf5e4Pharma Surgeen2026-08-06T00:00:00.000ZIncidence Profile of Side Effects of Anti-Tuberculosis Drugs and Adherence To Taking Medication In Tuberculosis Patients At The Sukolilo 1 Health Centerhttps://www.pharmaradar360.com/article/letter-to-the-editor-a-study-of-clinical-profile-chest-x-ray-ecg-changes-and-2d-15726b751d2490d5Pharma Surgeen2026-08-06T00:00:00.000ZLetter to the Editor: A Study of Clinical Profile, Chest X-ray, ECG Changes, and 2D Echocardiography in Patients with Chronic Cor Pulmonalehttps://www.pharmaradar360.com/article/real-world-patterns-of-analgesic-combination-therapy-and-their-associations-with-41aca5a25c09cdd2Pharma Surgeen2026-08-06T00:00:00.000ZReal-world patterns of analgesic combination therapy and their associations with pain intensity and treatment modification in patients with chronic non-cancer pain: A retrospective observational studyhttps://www.pharmaradar360.com/article/schwannoma-of-the-submandibular-gland-in-a-16-year-old-patient-a-clinical-case-r-27b236b465f6d243Pharma Surgeen2026-08-06T00:00:00.000ZSchwannoma of the submandibular gland in a 16-year-old patient: a clinical case repor thttps://www.pharmaradar360.com/article/micronutrients-in-pediatric-asthma-biological-mechanisms-and-clinical-evidence-a-19060791bafb3673Pharma Surgeen2026-08-06T00:00:00.000ZMicronutrients in Pediatric Asthma: Biological Mechanisms and Clinical Evidence—A Narrative Reviewhttps://www.pharmaradar360.com/article/predicting-aci-outcomes-with-gmp-in-process-control-kinetic-metrics-initial-chon-ff4645f8fbcb4df6Pharma Surgeen2026-08-06T00:00:00.000ZPredicting ACI Outcomes with GMP In-Process Control Kinetic Metrics: Initial Chondrocyte Yield and Population Doubling Time as Prognostic Clinical Biomarkershttps://www.pharmaradar360.com/article/exploring-multidimensional-diabetes-self-management-and-health-related-functioni-689ec46406c29999Pharma Surgeen2026-08-06T00:00:00.000ZExploring Multidimensional Diabetes Self-Management and Health-Related Functioning in Relation to Vascular Complicationshttps://www.pharmaradar360.com/article/an-evidence-informed-clinical-pathway-for-copd-exacerbations-in-emergency-depart-806f9ddd6eff8c05Pharma Surgeen2026-08-06T00:00:00.000ZAn Evidence-Informed Clinical Pathway for COPD Exacerbations in Emergency Departments: Diagnostic Assessment, Severity Stratification, and Individualized Managementhttps://www.pharmaradar360.com/article/clinical-impact-of-multidrug-resistant-bacterial-infections-in-critically-ill-pa-5450516556c2c575Pharma Surgeen2026-08-06T00:00:00.000ZClinical Impact of Multidrug-Resistant Bacterial Infections in Critically Ill Patients: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/imaging-based-markers-of-sarcopenia-in-lower-limb-ischemia-a-systematic-review-f066e8ec8a852b4cPharma Surgeen2026-08-06T00:00:00.000ZImaging-Based Markers of Sarcopenia in Lower Limb Ischemia: A Systematic Reviewhttps://www.pharmaradar360.com/article/diabetic-retinopathy-grading-and-concurrent-cardiorenal-biomarker-abnormalities-9723d5ad4177097ePharma Surgeen2026-08-06T00:00:00.000ZDiabetic Retinopathy Grading and Concurrent Cardiorenal Biomarker Abnormalities in Type 2 Diabetes: Albuminuria and Elevated NT-proBNP—A Retrospective Cross-Sectional Studyhttps://www.pharmaradar360.com/article/clinical-electrocardiographic-biochemical-and-echocardiographic-markers-for-diag-2bc18f22ceb43ea9Pharma Surgeen2026-08-06T00:00:00.000ZClinical, Electrocardiographic, Biochemical, and Echocardiographic Markers for Diagnosing Cardiac Dysfunction in Neonates with Hypoxic–Ischemic Encephalopathy: A Narrative Reviewhttps://www.pharmaradar360.com/article/clinical-cytological-grading-in-chronic-rhinosinusitis-with-nasal-polyps-an-inte-732b9c8092337fc7Pharma Surgeen2026-08-06T00:00:00.000ZClinical-Cytological Grading in Chronic Rhinosinusitis with Nasal Polyps: An Integrated Framework for Precision Medicinehttps://www.pharmaradar360.com/article/a-pilot-study-of-helicopter-emergency-medical-services-in-the-zhoushan-archipela-40fb5e93fff72314Pharma Surgeen2026-08-06T00:00:00.000ZA pilot study of helicopter emergency medical services in the Zhoushan Archipelago: clinical experience and operational insights from 18 caseshttps://www.pharmaradar360.com/article/participant-food-tracking-in-psychiatric-ketogenic-metabolic-therapy-an-unresolv-60ecff2d38798bc3Pharma Surgeen2026-08-06T00:00:00.000ZParticipant food tracking in psychiatric ketogenic metabolic therapy: an unresolved clinical, psychosocial, and implementation questionhttps://www.pharmaradar360.com/article/vitamin-b6-in-nausea-and-vomiting-of-pregnancy-metabolism-mechanisms-and-clinica-73c6ff3054a62547Pharma Surgeen2026-08-06T00:00:00.000ZVitamin B6 in nausea and vomiting of pregnancy: metabolism, mechanisms, and clinical implications—a narrative reviewhttps://www.pharmaradar360.com/article/clinical-characteristics-and-diagnostic-challenges-of-non-st-segment-elevation-a-e2009983645eb72cPharma Surgeen2026-08-06T00:00:00.000ZClinical characteristics and diagnostic challenges of non-ST-segment elevation acute coronary syndrome patients with normal electrocardiograms: a reviewhttps://www.pharmaradar360.com/article/demographic-and-clinical-characteristics-of-brachial-plexus-injury-at-kirtipur-h-5bdebebfa0ed85cdPharma Surgeen2026-08-06T00:00:00.000ZDemographic and Clinical Characteristics of Brachial Plexus Injury at Kirtipur Hospitalhttps://www.pharmaradar360.com/article/the-role-of-social-media-in-shaping-political-ideology-in-rural-india-7ac1621de271df21Pharma Surgeen2026-08-06T00:00:00.000ZTHE ROLE OF SOCIAL MEDIA IN SHAPING POLITICAL IDEOLOGY IN RURAL INDIAhttps://www.pharmaradar360.com/article/forensic-accounting-adoption-across-diverse-organizational-settings-development-3f75c9772adf2b5dPharma Surgeen2026-08-06T00:00:00.000ZForensic Accounting Adoption Across Diverse Organizational Settings: Development Of A Best-Practice Compendium For Systematic Implementationhttps://www.pharmaradar360.com/article/cardiovascular-morbidity-and-dyslipidaemia-across-the-spectrum-of-hypothyroidism-c935166a60c8a89dPharma Surgeen2026-08-06T00:00:00.000ZCardiovascular Morbidity and Dyslipidaemia Across the Spectrum of Hypothyroidism: A Cross-Sectional Study from a Tertiary Care Centre in Southern Indiahttps://www.pharmaradar360.com/article/psychological-well-being-occupational-stress-and-resilience-among-ambulance-driv-9c054c681b930fd6Pharma Surgeen2026-08-06T00:00:00.000ZPsychological Well-Being, Occupational Stress and Resilience among Ambulance Drivers in Emergency Medical Serviceshttps://www.pharmaradar360.com/article/development-of-a-topical-gel-containing-5-fluorouracil-loaded-microsponges-for-s-f54ea3d3dff1f828Pharma Surgeen2026-08-06T00:00:00.000ZDevelopment of a Topical Gel Containing 5-Fluorouracil-Loaded Microsponges for Sustained Drug Deliveryhttps://www.pharmaradar360.com/article/laser-versus-ultrasound-at-acupuncture-points-on-chronic-non-specific-low-back-p-3fa30aad3a264c08Pharma Surgeen2026-08-06T00:00:00.000ZLaser Versus Ultrasound at Acupuncture Points on Chronic Non-Specific Low Back Painhttps://www.pharmaradar360.com/article/development-and-in-vivo-characterization-of-calcipotriol-niosomal-gel-for-psoria-db6924ca2fc59430Pharma Surgeen2026-08-06T00:00:00.000ZDevelopment and In Vivo Characterization of Calcipotriol Niosomal Gel for Psoriasis Managementhttps://www.pharmaradar360.com/article/polyherbal-fruit-peel-formulation-of-annona-squamosa-malus-domestica-psidium-gua-88a35cee1e8ed422Pharma Surgeen2026-08-06T00:00:00.000ZPolyherbal Fruit Peel Formulation of Annona squamosa, Malus domestica, Psidium guajava, and Punica granatum Attenuates Diabetic Neuropathy in Streptozotocin-Induced Rats.https://www.pharmaradar360.com/article/infant-feeding-practices-among-the-oraon-tribal-mothers-in-sundargarh-district-o-d55d4e46a02f808fPharma Surgeen2026-08-06T00:00:00.000ZInfant Feeding Practices among the Oraon Tribal Mothers in Sundargarh District of Odishahttps://www.pharmaradar360.com/article/deciphering-the-biophysical-properties-of-a-novel-linear-conotoxin-recombinant-e-a11b827cdc436a69Pharma Surgeen2026-08-06T00:00:00.000ZDeciphering the Biophysical Properties of a Novel Linear Conotoxin: Recombinant Expression and Profiling of Mo1692https://www.pharmaradar360.com/article/a-study-to-assess-the-level-of-perfectionism-and-health-status-among-undergradua-520c4187d5af8e78Pharma Surgeen2026-08-06T00:00:00.000ZA study to assess the level of perfectionism and health status among undergraduates of a selected College of Nursing, Ludhiana, Punjabhttps://www.pharmaradar360.com/article/proton-coupled-alternating-access-in-a-versatile-mycobacterial-spns-drug-transpo-a33b51a401e0e11aPharma Surgeen2026-08-06T00:00:00.000ZProton-coupled alternating access in a versatile mycobacterial Spns drug transporterhttps://www.pharmaradar360.com/article/water-conservation-and-circular-water-reuse-in-clinical-hemodialysis-facilities-7c55e2bd442d1423Pharma Surgeen2026-08-06T00:00:00.000ZWater conservation and circular water reuse in clinical hemodialysis facilities: a scoping reviewhttps://www.pharmaradar360.com/article/structural-decoupling-index-based-characterization-of-hierarchical-brain-structu-0783aad759510f06Pharma Surgeen2026-08-06T00:00:00.000ZStructural decoupling index–based characterization of hierarchical brain structure–function coupling alterations and their clinical and molecular associations in migraine: a cross-sectional studyhttps://www.pharmaradar360.com/article/chemotherapy-response-score-as-a-surrogate-endpoint-for-clinical-efficacy-of-neo-6d802be4e8f42c17Pharma Surgeen2026-08-06T00:00:00.000ZChemotherapy Response Score as a surrogate endpoint for clinical efficacy of neoadjuvant durvalumab and tremelimumab in combination with chemotherapy in newly diagnosed advanced high grade serous ovarian cancer (iPRIME): A randomized, non-comparative phase 2 clinical trialhttps://www.pharmaradar360.com/article/integrated-clinical-environmental-and-healthcare-worker-hand-surveillance-for-un-edfb021d374f4664Pharma Surgeen2026-08-06T00:00:00.000ZIntegrated clinical, environmental, and healthcare-worker hand surveillance for unit-level infection prevention prioritisation in a Mongolian tertiary hospital: a two-component observational studyhttps://www.pharmaradar360.com/article/effect-of-plasma-rich-in-growth-factor-with-bridge-flap-in-management-of-miller-d44dfdecf11df131Pharma Surgeen2026-08-06T00:00:00.000ZEffect of Plasma rich in growth factor with bridge flap in management of Miller’s class I and II gingival recession defects: a comparative clinical studyhttps://www.pharmaradar360.com/article/sharing-tales-that-teach-protocol-for-a-cohort-embedded-randomised-trial-of-care-d97e6a8a49e07643Pharma Surgeen2026-08-06T00:00:00.000ZSharing Tales That Teach: Protocol for a cohort-embedded randomised trial of caregiver-delivered emotion-focused shared reading in young childrenhttps://www.pharmaradar360.com/article/a-phase-ii-trial-of-adi-peg20-in-combination-with-gemcitabine-and-docetaxel-for-5a03ec04a05c4090Pharma Surgeen2026-08-06T00:00:00.000ZA Phase II Trial of ADI-PEG20 in Combination with Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcomahttps://www.pharmaradar360.com/article/clinical-case-of-repeated-pregnancy-during-the-menstrual-cycle-following-medicat-ab52ff1e93896ae1Pharma Surgeen2026-08-06T00:00:00.000ZClinical case of repeated pregnancy during the menstrual cycle following medication abortion.https://www.pharmaradar360.com/article/salivary-thioredoxin-1-as-a-non-invasive-redox-biomarker-in-oral-diseases-84492672d18a72d6Pharma Surgeen2026-08-06T00:00:00.000ZSalivary thioredoxin-1 as a non-invasive redox biomarker in oral diseaseshttps://www.pharmaradar360.com/article/monostotic-chronic-nonbacterial-osteomyelitis-chronic-recurrent-multifocal-osteo-5cd09a887570ef0aPharma Surgeen2026-08-06T00:00:00.000ZMonostotic chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis of clavicle mimicking malignant bone tumor: A case report and review of literaturehttps://www.pharmaradar360.com/article/irritable-bowel-syndrome-and-colon-cancer-a-meta-analysis-ed1d6ea487d76d8ePharma Surgeen2026-08-06T00:00:00.000ZIrritable bowel syndrome and colon cancer: A meta-analysishttps://www.pharmaradar360.com/article/laparoscopic-repair-of-a-rare-morgagni-hernia-a-case-report-af3ce262350005b7Pharma Surgeen2026-08-06T00:00:00.000ZLaparoscopic repair of a rare Morgagni hernia: A case reporthttps://www.pharmaradar360.com/article/the-role-of-magnetic-resonance-imaging-in-sports-injuries-current-applications-a-ce8235f79f5706bcPharma Surgeen2026-08-06T00:00:00.000ZThe Role of Magnetic Resonance Imaging in Sports Injuries: Current Applications and Clinical Importance - A Narrative Reviewhttps://www.pharmaradar360.com/article/the-therapeutic-landscape-of-cannabidiol-a-systematic-review-of-molecular-mechan-ef13709a479c81d7Pharma Surgeen2026-08-06T00:00:00.000ZThe therapeutic landscape of cannabidiol: a systematic review of molecular mechanisms, clinical efficacy in oncology and neurology, and regulatory changeshttps://www.pharmaradar360.com/article/correction-18f-fdg-pet-ct-performs-better-than-ct-in-determining-the-bone-biopsy-bb5ea796f4ee2dd0Pharma Surgeen2026-08-06T00:00:00.000ZCorrection: [18F]FDG PET/CT performs better than CT in determining the bone biopsy site : randomized controlled clinical trialhttps://www.pharmaradar360.com/article/predictors-of-target-lesion-failure-in-patients-with-in-stent-restenosis-insight-387ab2ecbb6f01f1Pharma Surgeen2026-08-06T00:00:00.000ZPredictors of Target Lesion Failure in Patients With In-Stent Restenosis: Insights From the AGENT IDE Trialhttps://www.pharmaradar360.com/article/phylogenetic-diversity-of-pseudomonas-aeruginosa-from-diverse-clinical-infection-ea86ab55a57bb231Pharma Surgeen2026-08-06T00:00:00.000ZPhylogenetic Diversity of Pseudomonas aeruginosa from Diverse Clinical Infections Based on 16S rRNA Gene Sequence Analysishttps://www.pharmaradar360.com/article/nutritional-assessment-in-the-era-of-precision-nutrition-from-measurement-to-mea-446d98a38e3475cbPharma Surgeen2026-08-06T00:00:00.000ZNutritional assessment in the era of precision nutrition: from measurement to meaninghttps://www.pharmaradar360.com/article/associations-between-antiparietal-cell-antibody-values-and-atrophy-in-a-south-an-870118e7770efd06Pharma Surgeen2026-08-06T00:00:00.000ZAssociations Between Antiparietal Cell Antibody Values and Atrophy in a South and Southeast Asian General Populationhttps://www.pharmaradar360.com/article/the-role-of-artificial-intelligence-combined-with-digital-cholangioscopy-for-ind-d6c2abe6024dfcdbPharma Surgeen2026-08-06T00:00:00.000ZThe Role of Artificial Intelligence Combined With Digital Cholangioscopy for Indeterminant and Malignant Biliary Strictureshttps://www.pharmaradar360.com/article/two-new-stroke-clinical-trials-evaluate-worth-of-combination-therapies-b423bb36cd6e4abbPharma Surgeen2026-08-06T00:00:00.000ZTwo New Stroke Clinical Trials Evaluate Worth of Combination Therapieshttps://www.pharmaradar360.com/article/pharmacogenomic-biomarkers-in-oncology-evidence-clinical-utility-and-barriers-to-d6c662f0b66e9924Pharma Surgeen2026-08-06T00:00:00.000ZPharmacogenomic biomarkers in oncology: evidence, clinical utility, and barriers to implementationhttps://www.pharmaradar360.com/article/conservative-oxygen-for-unresponsive-patients-after-cardiac-arrest-2e31edc2dc9e00e8Pharma Surgeen2026-08-06T00:00:00.000ZConservative Oxygen for Unresponsive Patients after Cardiac Arresthttps://www.pharmaradar360.com/article/clinical-characteristics-of-patients-infected-with-bundibugyo-virus-drc-2026-28e3f76d2672ff2dPharma Surgeen2026-08-06T00:00:00.000ZClinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026https://www.pharmaradar360.com/article/combining-ai-interpretation-of-cholangiograms-and-clinical-data-for-postoperativ-c5220ba8379ba71aPharma Surgeen2026-08-06T00:00:00.000ZCombining AI interpretation of cholangiograms and clinical data for postoperative risk stratification after ERCP in cholodocholithiasishttps://www.pharmaradar360.com/article/clinical-and-radiographic-evaluation-of-natural-bovine-bone-with-hyaluronic-acid-a6f733b774ce64e2Pharma Surgeen2026-08-06T00:00:00.000ZClinical and radiographic evaluation of natural bovine bone with hyaluronic acid on osseointegration of immediate implants: a randomized clinical studyhttps://www.pharmaradar360.com/article/a-suite-of-engineered-mice-for-interrogating-psychedelic-drug-actions-649c4a7e0cb40078Pharma Surgeen2026-08-06T00:00:00.000ZA suite of engineered mice for interrogating psychedelic drug actionshttps://www.pharmaradar360.com/article/clinical-outcomes-following-insertion-of-second-generation-aspira-tunneled-indwe-88478d215089816ePharma Surgeen2026-08-06T00:00:00.000ZClinical outcomes following insertion of second-generation (Aspira®) tunneled indwelling peritoneal catheters to treat malignant asciteshttps://www.pharmaradar360.com/article/clinical-characteristics-etiologies-outcomes-and-complications-of-total-knee-art-9618ddb6bb2d831cPharma Surgeen2026-08-06T00:00:00.000ZClinical characteristics etiologies outcomes and complications of total knee arthroplasty in patients aged 18 to 54 years a nationwide inpatient sample analysishttps://www.pharmaradar360.com/article/efficacy-and-safety-of-high-dose-retatrutide-in-adults-with-obesity-and-type-2-d-6f92c9571c290734Pharma Surgeen2026-08-06T00:00:00.000ZEfficacy and Safety of High-Dose Retatrutide in Adults with Obesity and Type 2 Diabetes: A Systematic Review and Bayesian Meta-Analysishttps://www.pharmaradar360.com/article/undertriage-of-geriatric-trauma-patients-in-the-emergency-department-a-retrospec-f3037345923e5510Pharma Surgeen2026-08-06T00:00:00.000ZUndertriage of geriatric trauma patients in the emergency department: A retrospective single-center studyhttps://www.pharmaradar360.com/article/clinical-research-on-microecological-landscape-for-infection-risk-stratification-faa15ecc26ba4dc3Pharma Surgeen2026-08-06T00:00:00.000ZClinical Research on Microecological Landscape for Infection Risk Stratification in Newly Diagnosed Patients with Hematological Conditionshttps://www.pharmaradar360.com/article/effect-of-cyanoacrylate-tissue-adhesive-on-dehiscence-after-absorbable-membrane-b4d1c33ce4a70ed5Pharma Surgeen2026-08-06T00:00:00.000ZEffect of Cyanoacrylate Tissue Adhesive on Dehiscence After Absorbable Membrane Fixation in Oral Surgery: A Pilot Randomized Clinical Trialhttps://www.pharmaradar360.com/article/molecular-diagnostics-as-the-clinical-standard-in-cholangiocarcinoma-and-hepatoc-e7ff41e9ed3bbe3fPharma Surgeen2026-08-06T00:00:00.000ZMolecular diagnostics as the clinical standard in cholangiocarcinoma and hepatocellular carcinoma: a new era of precision oncologyhttps://www.pharmaradar360.com/article/antimicrobial-antibiofilm-and-virulence-gene-modulatory-effects-of-supercritical-06ba5c12a9fb97baPharma Surgeen2026-08-06T00:00:00.000ZAntimicrobial, antibiofilm, and virulence gene modulatory effects of supercritical CO₂ extracts of Thymbra spicata against clinical MRSA isolateshttps://www.pharmaradar360.com/article/genetic-characteristics-and-clinical-features-of-pediatric-congenital-adrenal-hy-e8793683b29d015dPharma Surgeen2026-08-06T00:00:00.000ZGenetic characteristics and clinical features of pediatric congenital adrenal hyperplasia in Koreahttps://www.pharmaradar360.com/article/renal-safety-of-amikacin-compared-with-ceftriaxone-in-patients-treated-for-urina-465d70b3d28ff294Pharma Surgeen2026-08-06T00:00:00.000ZRenal safety of amikacin compared with ceftriaxone in patients treated for urinary tract infection: an observational cohort studyhttps://www.pharmaradar360.com/article/improving-self-efficacy-through-nurse-navigation-in-patients-during-treatment-fo-a5df8b5657fef8a1Pharma Surgeen2026-08-06T00:00:00.000ZImproving self-efficacy through nurse navigation in patients during treatment for colorectal cancer: a randomized controlled trialhttps://www.pharmaradar360.com/article/modified-sutureless-flanged-intrascleral-intraocular-lens-fixation-in-pediatric-d5c4b86ba1750120Pharma Surgeen2026-08-06T00:00:00.000ZModified sutureless flanged intrascleral intraocular lens fixation in pediatric patients: clinical outcomes over 2 years of follow-uphttps://www.pharmaradar360.com/article/efficacy-and-safety-of-vunakizumab-in-patients-with-moderate-to-severe-plaque-ps-e77bf9fe39edfa4bPharma Surgeen2026-08-06T00:00:00.000ZEfficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trialhttps://www.pharmaradar360.com/article/association-and-discriminative-value-of-serum-inflammatory-biomarkers-for-sarcop-e0267c40f91e2c53Pharma Surgeen2026-08-06T00:00:00.000ZAssociation and discriminative value of serum inflammatory biomarkers for sarcopenic obesity: A retrospective cross‐sectional studyhttps://www.pharmaradar360.com/article/scp-i-umod-i-scp-genotype-and-clinical-outcomes-in-heart-failure-patients-treate-d63b2bdb1cad16ffPharma Surgeen2026-08-06T00:00:00.000Z<scp> <i>UMOD</i> </scp> Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A <scp>UK</scp> Biobank Pharmacogenetic Cohort Studyhttps://www.pharmaradar360.com/article/nct07751016-a-clinical-study-of-kh001-for-pulp-preservation-and-safety-in-deep-d-0a035e6663cd56daPharma Surgeen2026-08-06T00:00:00.000ZNCT07751016: A Clinical Study of KH001 for Pulp Preservation and Safety in Deep Dentin Carieshttps://www.pharmaradar360.com/article/nct07750990-an-extension-study-of-s-606001-in-participants-with-late-onset-pompe-662bef6eb058c7fePharma Surgeen2026-08-06T00:00:00.000ZNCT07750990: An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)https://www.pharmaradar360.com/article/nct07750964-intravascular-lithotripsy-versus-rotational-atherectomy-for-severe-c-422f578c19513722Pharma Surgeen2026-08-06T00:00:00.000ZNCT07750964: Intravascular Lithotripsy Versus Rotational Atherectomy for Severe Coronary Artery Calcification: A Prospective, Multicenter, Non-inferiority Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07750951-single-arm-phase-ii-clinical-study-evaluating-the-safety-and-efficac-9737a1120b2fa912Pharma Surgeen2026-08-06T00:00:00.000ZNCT07750951: Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancerhttps://www.pharmaradar360.com/article/nct07750522-correlation-between-mri-findings-and-clinical-improvement-following-da36dfc4095e08bcPharma Surgeen2026-08-06T00:00:00.000ZNCT07750522: Correlation Between MRI Findings and Clinical Improvement Following TMJ Injection With Hyaluronic Acid and Platelet-Rich Plasmahttps://www.pharmaradar360.com/article/nct07750483-efficacy-of-intra-articular-hyaluronic-acid-combination-injections-f-0e9609098e1e0821Pharma Surgeen2026-08-06T00:00:00.000ZNCT07750483: Efficacy of Intra-Articular Hyaluronic Acid Combination Injections for Temporomandibular Joint Internal Derangement: A Clinical and MRI Based Randomized Trialhttps://www.pharmaradar360.com/article/nct07750080-the-effect-of-multimodal-approach-of-electrotherapy-versus-shock-wav-7556f09e26f83423Pharma Surgeen2026-08-06T00:00:00.000ZNCT07750080: The Effect of Multimodal Approach of Electrotherapy Versus Shock Wave Therapy in Menopausal Women With Tennis Elbow.https://www.pharmaradar360.com/article/nct07749859-shr-1701-plus-apatinib-for-second-line-treatment-in-targeted-immune-675738c163ff98c1Pharma Surgeen2026-08-06T00:00:00.000ZNCT07749859: SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinomahttps://www.pharmaradar360.com/article/nct07749443-construction-and-empirical-study-of-indirect-intervention-model-for-2c0d086c6f1bae73Pharma Surgeen2026-08-06T00:00:00.000ZNCT07749443: Construction and Empirical Study of Indirect Intervention Model for Protective Medical Lung Cancer Patients Based on Family System Theoryhttps://www.pharmaradar360.com/article/nct07749365-hypofractionated-radiotherapy-plus-gm-csf-pomalidomide-and-glofitama-b62a051c0ac538c9Pharma Surgeen2026-08-06T00:00:00.000ZNCT07749365: Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLhttps://www.pharmaradar360.com/article/nct07749326-conventional-versus-stomach-partitioning-gastrojejunostomy-for-malig-96d201d321344da9Pharma Surgeen2026-08-06T00:00:00.000ZNCT07749326: Conventional Versus Stomach-Partitioning Gastrojejunostomy for Malignant Gastric Outlet Obstruction in Stage IV Gastric Cancer (KLASS 16)https://www.pharmaradar360.com/article/nct07749118-hb05p-on-muscle-health-3b111b7fd32435dcPharma Surgeen2026-08-06T00:00:00.000ZNCT07749118: HB05P on Muscle Healthhttps://www.pharmaradar360.com/article/nct07749014-timing-of-empagliflozin-in-primary-pci-pre-reperfusion-versus-post-r-ec2022e041272e37Pharma Surgeen2026-08-06T00:00:00.000ZNCT07749014: Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patientshttps://www.pharmaradar360.com/article/nct07736950-a-study-comparing-a-new-drug-surovatamig-with-standard-radiotherapy-eb5ed01787f34c40Pharma Surgeen2026-08-06T00:00:00.000ZNCT07736950: A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphomahttps://www.pharmaradar360.com/article/nct07673250-personalized-ventilator-settings-for-patients-on-ecmo-92083d2952c2f6bfPharma Surgeen2026-08-06T00:00:00.000ZNCT07673250: Personalized Ventilator Settings for Patients on ECMOhttps://www.pharmaradar360.com/article/nct07670130-venetoclax-tdm-in-newly-diagnosed-aml-exposure-response-and-prognosi-da20f68ea07b6a31Pharma Surgeen2026-08-06T00:00:00.000ZNCT07670130: Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosishttps://www.pharmaradar360.com/article/nct07659795-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-colore-1e87418e21d161a4Pharma Surgeen2026-08-06T00:00:00.000ZNCT07659795: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancerhttps://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2Pharma Surgeen2026-08-06T00:00:00.000ZNCT07619547: Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Diseasehttps://www.pharmaradar360.com/article/nct07512271-generative-ai-patient-education-module-for-breast-oncology-7af8ec835c719fc5Pharma Surgeen2026-08-06T00:00:00.000ZNCT07512271: Generative AI Patient Education Module for Breast Oncologyhttps://www.pharmaradar360.com/article/nct07504744-klotho-gene-red-complex-bacteria-and-periodontal-viruses-in-patients-02adad767543ba3ePharma Surgeen2026-08-06T00:00:00.000ZNCT07504744: Klotho Gene, Red Complex Bacteria and Periodontal Viruses in Patients With and Without Periodontitis and Acute Coronary Syndromehttps://www.pharmaradar360.com/article/nct07444619-a-phase-i-study-of-pazopanib-in-combination-with-trabectedin-ipilimu-633f6a2812b16cafPharma Surgeen2026-08-06T00:00:00.000ZNCT07444619: A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomashttps://www.pharmaradar360.com/article/nct07416526-a-clinical-study-to-evaluate-the-effects-of-nxt007-compared-to-facto-cac91fa417303aa7Pharma Surgeen2026-08-06T00:00:00.000ZNCT07416526: A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia Ahttps://www.pharmaradar360.com/article/nct07414836-a-first-in-human-study-of-bg-c0979-in-adults-with-advanced-solid-tum-70664b213e834f97Pharma Surgeen2026-08-06T00:00:00.000ZNCT07414836: A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumorshttps://www.pharmaradar360.com/article/nct07388550-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-po-c8883fe8549f9913Pharma Surgeen2026-08-06T00:00:00.000ZNCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)https://www.pharmaradar360.com/article/nct07365319-a-safety-and-efficacy-study-of-eik1001-in-combination-with-pembroliz-bcb24a2a3b5a90cfPharma Surgeen2026-08-06T00:00:00.000ZNCT07365319: A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.https://www.pharmaradar360.com/article/nct07351019-colonoscopy-bowel-prep-comparison-among-diabetic-patients-9be355143b6d87a6Pharma Surgeen2026-08-06T00:00:00.000ZNCT07351019: Colonoscopy Bowel Prep Comparison Among Diabetic Patientshttps://www.pharmaradar360.com/article/nct07286149-a-clinical-study-of-mk-1084-with-other-treatments-for-non-small-cell-648cb14517924585Pharma Surgeen2026-08-06T00:00:00.000ZNCT07286149: A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)https://www.pharmaradar360.com/article/nct07279571-gyn-aide-gynecologic-oncology-navigation-through-ai-driven-education-b93f43d09bf2fd5fPharma Surgeen2026-08-06T00:00:00.000ZNCT07279571: GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Educationhttps://www.pharmaradar360.com/article/nct07227168-a-study-of-stro-004-in-adults-with-refractory-recurrent-metastatic-c-667f1185630cecb5Pharma Surgeen2026-08-06T00:00:00.000ZNCT07227168: A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancerhttps://www.pharmaradar360.com/article/nct07226843-a-study-of-ly4584180-in-adult-participants-with-previously-treated-b-b4fe8c2e70e70af3Pharma Surgeen2026-08-06T00:00:00.000ZNCT07226843: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancershttps://www.pharmaradar360.com/article/nct07223593-efficacy-and-safety-of-orforglipron-in-participants-with-peripheral-7a77928837a4f67fPharma Surgeen2026-08-06T00:00:00.000ZNCT07223593: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Diseasehttps://www.pharmaradar360.com/article/nct07220642-weight-loss-in-people-living-with-overweight-or-obesity-following-tr-0d1daa40acb3f757Pharma Surgeen2026-08-06T00:00:00.000ZNCT07220642: Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintidehttps://www.pharmaradar360.com/article/nct07161999-study-of-coya-302-for-the-treatment-of-als-2f204435e7f53893Pharma Surgeen2026-08-06T00:00:00.000ZNCT07161999: Study of COYA 302 for the Treatment of ALShttps://www.pharmaradar360.com/article/nct07159204-polymeric-micellar-paclitaxel-based-combination-therapy-for-advanced-21d17d9284aef7d0Pharma Surgeen2026-08-06T00:00:00.000ZNCT07159204: Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancerhttps://www.pharmaradar360.com/article/nct07114601-a-study-of-ly4257496-in-participants-with-cancer-omniray-445abbd3d05bc59fPharma Surgeen2026-08-06T00:00:00.000ZNCT07114601: A Study of LY4257496 in Participants With Cancer (OMNIRAY)https://www.pharmaradar360.com/article/nct07101666-total-neoadjuvant-therapy-with-short-course-radiation-therapy-in-gas-ab09fa5c1134df23Pharma Surgeen2026-08-06T00:00:00.000ZNCT07101666: Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancerhttps://www.pharmaradar360.com/article/nct07042191-a-provider-intervention-to-reduce-financial-toxicity-in-patients-wit-815cbaaec21ea79fPharma Surgeen2026-08-06T00:00:00.000ZNCT07042191: A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussionshttps://www.pharmaradar360.com/article/nct07024706-phase-2-study-of-disease-risk-mutation-guided-finite-acalabrutinib-v-eabd9cccf2a1e8e2Pharma Surgeen2026-08-06T00:00:00.000ZNCT07024706: Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumabhttps://www.pharmaradar360.com/article/nct07023627-a-study-of-incb123667-in-participants-with-platinum-resistant-ovaria-0431f082659a8eb0Pharma Surgeen2026-08-06T00:00:00.000ZNCT07023627: A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpressionhttps://www.pharmaradar360.com/article/nct06783309-cnp-103-in-adolescent-and-adult-subjects-ages-12-35-with-recently-di-081a430772a57e08Pharma Surgeen2026-08-06T00:00:00.000ZNCT06783309: CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)https://www.pharmaradar360.com/article/nct06747884-trial-readiness-and-endpoint-assessment-in-pediatric-myotonic-dystro-24562aba587c4986Pharma Surgeen2026-08-06T00:00:00.000ZNCT06747884: Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extensionhttps://www.pharmaradar360.com/article/nct06716866-temporally-interfering-electric-field-stimulation-in-the-treatment-o-037558299deb987dPharma Surgeen2026-08-06T00:00:00.000ZNCT06716866: Temporally Interfering Electric Field Stimulation in the Treatment of Epilepsyhttps://www.pharmaradar360.com/article/nct06705920-effect-of-topical-active-oxygen-therapy-on-surgical-site-wound-heali-1ddc024dfae6d5cfPharma Surgeen2026-08-06T00:00:00.000ZNCT06705920: Effect of Topical Active Oxygen Therapy on Surgical Site Wound Healing and Microbial Colonizationhttps://www.pharmaradar360.com/article/nct06615973-screening-for-social-determinants-of-health-sdoh-and-cognitive-funct-69af5e89852e6a1aPharma Surgeen2026-08-06T00:00:00.000ZNCT06615973: Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Strokehttps://www.pharmaradar360.com/article/nct06602908-functional-status-for-surgically-and-non-surgically-treated-patients-7e40924566f57403Pharma Surgeen2026-08-06T00:00:00.000ZNCT06602908: Functional Status for Surgically and Non-surgically Treated Patients With Acute Achilles Tendon Rupture Following a Public Municipal Rehabilitationhttps://www.pharmaradar360.com/article/nct06600568-novel-therapeutic-approach-for-human-t-cell-malignancies-ffc94f4cc50ff29dPharma Surgeen2026-08-06T00:00:00.000ZNCT06600568: Novel Therapeutic Approach for Human T-cell Malignancieshttps://www.pharmaradar360.com/article/nct06498713-patient-controlled-administration-of-liquid-acetaminophen-206ca720cd2fa050Pharma Surgeen2026-08-06T00:00:00.000ZNCT06498713: Patient Controlled Administration of Liquid Acetaminophenhttps://www.pharmaradar360.com/article/nct06338995-a-study-of-lebrikizumab-ly3650150-in-participants-with-chronic-rhino-b8b1b604062053efPharma Surgeen2026-08-06T00:00:00.000ZNCT06338995: A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)https://www.pharmaradar360.com/article/nct06203600-adding-nivolumab-to-usual-treatment-for-people-with-advanced-stomach-520cb5d107702f36Pharma Surgeen2026-08-06T00:00:00.000ZNCT06203600: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trialhttps://www.pharmaradar360.com/article/nct05874297-online-nutrition-education-to-decrease-the-side-effects-of-chemother-25dc50f86ef36a93Pharma Surgeen2026-08-06T00:00:00.000ZNCT05874297: Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancerhttps://www.pharmaradar360.com/article/nct05553912-qbsafe-a-randomized-trial-of-a-novel-intervention-to-improve-care-fo-e4ad707f89ce3a1aPharma Surgeen2026-08-06T00:00:00.000ZNCT05553912: QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes.https://www.pharmaradar360.com/article/nct05401110-study-of-osimertinib-with-carotuximab-in-advanced-egfr-mutated-non-s-c63735c39f0c8bb7Pharma Surgeen2026-08-06T00:00:00.000ZNCT05401110: Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct05107115-rilzabrutinib-for-the-treatment-of-chronic-spontaneous-urticaria-in-626d7b7ad7ad6e43Pharma Surgeen2026-08-06T00:00:00.000ZNCT05107115: Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistaminehttps://www.pharmaradar360.com/article/nct05099003-a-study-of-the-drug-selinexor-with-radiation-therapy-in-patients-wit-fdb8c67fe54a8079Pharma Surgeen2026-08-06T00:00:00.000ZNCT05099003: A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)https://www.pharmaradar360.com/article/nct04269902-testing-early-treatment-for-patients-with-high-risk-chronic-lymphocy-cf81092206932f4ePharma Surgeen2026-08-06T00:00:00.000ZNCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Studyhttps://www.pharmaradar360.com/article/nct04221542-study-of-amg-509-in-participants-with-metastatic-castration-resistan-4aba1c68f6312c9bPharma Surgeen2026-08-06T00:00:00.000ZNCT04221542: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancerhttps://www.pharmaradar360.com/article/nct03277703-flu-vaccine-response-in-patients-on-biologic-therapies-5f692b12da2d666aPharma Surgeen2026-08-06T00:00:00.000ZNCT03277703: Flu Vaccine Response in Patients on Biologic Therapieshttps://www.pharmaradar360.com/article/nct02453282-phase-iii-open-label-first-line-therapy-study-of-medi-4736-durvaluma-61f6e610fe6d9f93Pharma Surgeen2026-08-06T00:00:00.000ZNCT02453282: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)https://www.pharmaradar360.com/article/nct02313571-breakthrough-pain-computer-integrated-patient-controlled-epidural-an-bed1529a36f74911Pharma Surgeen2026-08-06T00:00:00.000ZNCT02313571: Breakthrough Pain Computer Integrated Patient Controlled Epidural Analgesiahttps://www.pharmaradar360.com/article/3-healthcare-stocks-retail-investors-are-watching-as-hiring-slows-7ac4a278f8d5d47fPharma Surgeen2026-08-05T23:41:18.000Z3 Healthcare Stocks Retail Investors Are Watching As Hiring Slowshttps://www.pharmaradar360.com/article/gillibrand-scott-press-fda-on-shortage-of-cancer-drugs-b83116e1677725abPharma Surgeen2026-08-05T23:00:00.000ZGillibrand, Scott press FDA on shortage of cancer drugshttps://www.pharmaradar360.com/article/us-fda-approves-takeda-s-sleep-disorder-pill-be4cb3a9110ed9d5Pharma Surgeen2026-08-05T22:48:03.000ZUS FDA approves Takeda's sleep disorder pillhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-08664695aaeafb3fPharma Surgeen2026-08-05T22:48:03.000ZTakeda Pharmaceutical Company Limitedhttps://www.pharmaradar360.com/article/the-logo-of-japanese-takeda-pharmaceutical-co-is-seen-at-an-office-building-in-g-96d3d088d849662cPharma Surgeen2026-08-05T22:47:49.000ZThe logo of Japanese Takeda Pharmaceutical Co is seen at an office building in Glattbrugghttps://www.pharmaradar360.com/article/maharashtra-food-and-drug-administration-places-one-year-ban-on-analogue-non-dai-abdb416185bd8230Pharma Surgeen2026-08-05T22:44:40.000ZMaharashtra Food and Drug Administration places one-year ban on analogue, non-dairy paneerhttps://www.pharmaradar360.com/article/fda-finalizes-antimicrobial-animal-drug-safety-guidance-c256962891a03a40Pharma Surgeen2026-08-05T22:13:52.000ZFDA finalizes antimicrobial animal drug safety guidancehttps://www.pharmaradar360.com/article/victory-medical-center-pharmacy-issues-voluntary-nationwide-recall-of-certain-lo-76991f9cf5f6d723Pharma Surgeen2026-08-05T22:06:22.000ZVictory Medical Center Pharmacy Issues Voluntary Nationwide Recall of Certain Lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials Due to Elevated Endotoxin Levelshttps://www.pharmaradar360.com/article/vir-biotech-earnings-beat-by-0-14-revenue-topped-estimates-deae90193e64929cPharma Surgeen2026-08-05T21:45:00.000ZVir Biotech earnings beat by $0.14, revenue topped estimateshttps://www.pharmaradar360.com/article/biotech-backed-psoriasis-skincare-d9963547d37bd9afPharma Surgeen2026-08-05T21:39:41.000ZBiotech-Backed Psoriasis Skincarehttps://www.pharmaradar360.com/article/top-portage-biotech-alp-competitors-2026-f77a722fc11c05f7Pharma Surgeen2026-08-05T21:36:25.000ZTop Portage Biotech (ALP) Competitors 2026https://www.pharmaradar360.com/article/major-expansion-of-community-mental-health-support-across-england-a2cb994842375abbPharma Surgeen2026-08-05T21:30:02.000ZMajor expansion of community mental health support across Englandhttps://www.pharmaradar360.com/article/pharmaceutical-technology-launches-premium-subscription-service-for-industry-dat-a78dc29dd3e2ba00Pharma Surgeen2026-08-05T21:24:05.000ZPharmaceutical Technology Launches Premium Subscription Service for Industry Data and Analysishttps://www.pharmaradar360.com/article/biotech-ipo-fever-shows-no-signs-of-breaking-807c4e539d48cd54Pharma Surgeen2026-08-05T21:19:25.000ZBiotech IPO Fever Shows No Signs of Breakinghttps://www.pharmaradar360.com/article/applied-biologics-gains-irb-approval-for-phase-3-bioxheal-trial-in-diabetic-foot-a4970671f1d1be39Pharma Surgeen2026-08-05T21:15:33.000ZApplied Biologics Gains IRB Approval for Phase 3 BIOxHEAL Trial in Diabetic Foot Ulcers